Schistosomiasis Infections and Infestations Schistosomiasis
Conditions
Interventions
This study has four treatment arms - Two stool samples (study 1), three urine samples (study 2) and one blood finger prick sample will be collected if possible on two consecutive days or otherwise wit
Sponsors
Geigy Foundation
European Research Council
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent signed by parents and/or legal guardian, and oral assent by children 2. Able and willing to be examined by a study physician at the beginning of the study 3. Able and willing to provide two stool samples, three urine samples and one finger prick test at baselin and approximately three weeks after treatment (follow-up) 4. Positive for S. mansoni or S. haematobium eggs in the stool and/or in urine 5. Absence of major systemic illnesses (e.g. cancer, diabetes, clinical malaria or hepato-splenic schistosomiasis) as assessed by a medical doctor, upon initial clinical assessment 6. No known or reported history of chronic illness, e.g. cancer, diabetes, chronic heart, liver or renal disease 7. No anthelminthic or antimalarial treatments within past 4 weeks 8. No known allergy to study medications
Exclusion criteria
Exclusion criteria: 1. No written informed consent by parents and/or legal guardian 2. Presence of any abnormal medical condition, judged by the study physician. 3. History of acute or severe chronic disease such as cancer, diabetes, chronic heart, liver or renal disease 4. Recent use of anthelminthic or antimalarial drugs (within past 4 weeks) 5. Attending other clinical trials during the study 6. Negative diagnostic result for S. mansoni or S. haematobium (absence of helminth eggs in stool/urine)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: cure and egg reduction rate of S. mansoni and S. haematobium | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Drug safety 2. Cure and egg reduction rate against possible co-infections (Ascaris lumbricoides, Trichuris trichiura, hookworm Strongyloides stercoralis) 3. To determine the efficacy of Synriam® against malaria infection | — |
Countries
Cote d'Ivoire
Outcome results
None listed